J&J’s vaccine was authorized for US in last month, adding a third shot to the country’s mass inoculation efforts.
Like many countries, Canada does not have domestic production and has struggled with an immediate shortage of vaccines.
The Johnson & Johnson vaccine is what’s called a viral vector vaccine.
To create this vaccine, the Johnson & Johnson team took a harmless adenovirus – the viral vector – and replaced a small piece of its genetic instructions with coronavirus genes for the SARS-CoV-2 spike protein.
The FDA’s analysis found that, in the U.S., the Johnson & Johnson COVID-19 vaccine was 72% effective at preventing all COVID-19 and 86% effective at preventing severe cases of the disease. While there is still a chance a vaccinated person could get sick, this suggests they would be much less likely to need hospitalization or to die from COVID-19.
Earlier, US President Joe Biden announced that Merck & Co. will help make Johnson & Johnson’s single-shot Covid-19 vaccine -- a collaboration between rivals as the immunization race narrows and governments race to ramp up supply before dangerous new variants of the virus further erupt.